Home > Insider Trading > Filing (0001562180-22-000587)

Filing Details

Accession Number:: 0001562180-22-000587
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2022-01-24 06:01:39
Reporting Period:: 2022-01-19

Accepted Time:: 2022-01-24 06:01:39
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1689813	Biohaven Pharmaceutical Holding Co Ltd.	BHVN	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1878290	C. George Clark	C/O Biohaven Pharmaceuticals, Inc. 215 Church Street New Haven CT 06510	Vp, Chief Accounting Officer	No	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Shares	Acquisiton	2022-01-19	3,750	$53.76	13,470	No	4	M	Direct
Common Shares	Acquisiton	2022-01-19	1,920	$32.42	15,390	No	4	M	Direct
Common Shares	Disposition	2022-01-19	3,196	$114.93	12,194	No	4	S	Direct
Common Shares	Disposition	2022-01-19	2,159	$116.02	10,035	No	4	S	Direct
Common Shares	Disposition	2022-01-19	500	$118.05	9,535	No	4	S	Direct
Common Shares	Disposition	2022-01-19	3,520	$119.37	6,015	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Shares	Employee Stock Option (right to buy)	Disposition	2022-01-19	3,750	$0.00	3,750	$53.76
Common Shares	Employee Stock Option (right to buy)	Disposition	2022-01-19	1,920	$0.00	1,920	$32.42

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
4,500		2029-12-05	No	4	M	Direct
2,875		2028-11-20	No	4	M	Direct

Footnotes

These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.30 - $115.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.39 - $116.39, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.55 - $118.38, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $118.84 - $119.77, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
The shares underlying this option vest in four equal installments on December 5, 2019, 2020, 2021 and 2022, subject to the reporting person's continued service with the issuer at each vesting date.
The shares underlying this option vest in four equal installments on November 20, 2019, 2020, 2021 and 2022, subject to the reporting person's continued service with the issuer at each vesting date.